Ayala Pharmaceuticals, Inc.
If you purchased Ayala Pharmaceuticals, Inc. securities and would like to join the action, please click "Join This Action" below.
AYLA STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE MERGER OF AYALA PHARMACEUTICALS, INC. IS FAIR TO SHAREHOLDERS
October 19, 2022.
New York, New York—Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) and Advaxis, Inc. is fair to Ayala shareholders. Upon completion of the merger, Ayala stockholders would own approximately 62.5% of the combined company’s outstanding common stock.
The investigation concerns whether Ayala and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Ayala shareholders; and (2) disclose all material information necessary for Ayala shareholders to adequately assess and value the merger consideration. On behalf of Ayala shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.